JP2001524951A - 炎症性腸疾患を治療するための方法および組成物 - Google Patents

炎症性腸疾患を治療するための方法および組成物

Info

Publication number
JP2001524951A
JP2001524951A JP54099898A JP54099898A JP2001524951A JP 2001524951 A JP2001524951 A JP 2001524951A JP 54099898 A JP54099898 A JP 54099898A JP 54099898 A JP54099898 A JP 54099898A JP 2001524951 A JP2001524951 A JP 2001524951A
Authority
JP
Japan
Prior art keywords
mycobacterial
composition
product
treatment
rifabutin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP54099898A
Other languages
English (en)
Japanese (ja)
Inventor
トーマス ジュリアス ボロディー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO5940A external-priority patent/AUPO594097A0/en
Priority claimed from AUPO9785A external-priority patent/AUPO978597A0/en
Application filed by Individual filed Critical Individual
Publication of JP2001524951A publication Critical patent/JP2001524951A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP54099898A 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物 Withdrawn JP2001524951A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPO5940A AUPO594097A0 (en) 1997-04-01 1997-04-01 Novel methods of treating inflammatory bowel disease
AUPO9785A AUPO978597A0 (en) 1997-10-14 1997-10-14 Methods of treating inflammatory bowel disease
AU9785 1997-10-14
AU5940 1997-10-14
PCT/AU1998/000222 WO1998043667A1 (en) 1997-04-01 1998-04-01 Methods and compositions for treating inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007232402A Division JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物

Publications (1)

Publication Number Publication Date
JP2001524951A true JP2001524951A (ja) 2001-12-04

Family

ID=25645389

Family Applications (3)

Application Number Title Priority Date Filing Date
JP54099898A Withdrawn JP2001524951A (ja) 1997-04-01 1998-04-01 炎症性腸疾患を治療するための方法および組成物
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物
JP2012062968A Pending JP2012126736A (ja) 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007232402A Withdrawn JP2008024713A (ja) 1997-04-01 2007-09-07 炎症性腸疾患を治療するための方法および組成物
JP2012062968A Pending JP2012126736A (ja) 1997-04-01 2012-03-21 炎症性腸疾患を治療するための方法および組成物

Country Status (16)

Country Link
US (1) US6277836B1 (enExample)
EP (1) EP0971735B1 (enExample)
JP (3) JP2001524951A (enExample)
AR (1) AR012304A1 (enExample)
AT (1) ATE389417T1 (enExample)
CA (1) CA2285923C (enExample)
CY (1) CY1109783T1 (enExample)
DE (1) DE69839261T2 (enExample)
DK (1) DK0971735T3 (enExample)
ES (1) ES2303351T3 (enExample)
IL (1) IL132145A (enExample)
NO (1) NO325947B1 (enExample)
NZ (1) NZ500696A (enExample)
PT (1) PT971735E (enExample)
SI (1) SI0971735T1 (enExample)
WO (1) WO1998043667A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2013508428A (ja) * 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
KR20140082982A (ko) 2011-09-20 2014-07-03 레드힐 바이오파마 엘티디 자기 면역 질환 치료용 조성물 및 방법

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPP325398A0 (en) * 1998-04-30 1998-05-21 Borody, Thomas J. Improved method for eradicating h. pylori
ATE446767T1 (de) * 1999-02-12 2009-11-15 Univ Washington Gm-csf zur behandlung von morbus crohn
ES2231275T3 (es) 1999-10-08 2005-05-16 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
JP3369535B2 (ja) 1999-11-09 2003-01-20 松下電器産業株式会社 プラズマディスプレイ装置
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
ATE311358T1 (de) 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
JP4387804B2 (ja) * 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド ＦａｂＩ阻害剤
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
AUPS088702A0 (en) * 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
PT1575951E (pt) 2002-12-06 2014-09-15 Debiopharm Int Sa Compostos heterocíclicos, métodos para os preparar e sua utilização em terapia
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
AU2004314731B2 (en) * 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
JP2007520495A (ja) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法
US20080306029A1 (en) * 2004-05-28 2008-12-11 Salix Pharmaceuticals, Inc. Prevention, Treatment, and Amelioration of Radiation Induced Enteritis
US8450307B2 (en) * 2004-06-04 2013-05-28 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CA2816276A1 (en) * 2005-08-24 2007-03-01 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture and use thereof
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US20090156578A1 (en) * 2005-12-05 2009-06-18 PAULS Henry 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008098374A1 (en) * 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US20090098088A1 (en) * 2007-10-10 2009-04-16 The Procter & Gamble Company Methods And Kits For The Treatment Of Diverticular Conditions
US20090131343A1 (en) * 2007-11-15 2009-05-21 Ly Tam Phan Use of bridged macrolides or tylosin derivatives in treating inflammatory bowel diseases
CA2721981A1 (en) * 2008-05-01 2009-11-05 The Procter & Gamble Company Methods and kits for the treatment of inflammatory bowel disorder conditions
WO2011044140A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Substituted thioacetic acid salicylate derivatives and their uses
BR122014009845A2 (pt) 2010-04-26 2015-12-29 Salix Pharmaceuticals Ltd usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa
BR112013014827A2 (pt) 2010-12-13 2016-10-04 Antony Wettstein formulações gástricas e colônicas e métodos para produzir e usar as mesmas
EP2861608B8 (en) 2012-06-19 2019-06-19 Debiopharm International SA Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
NZ704014A (en) 2012-07-27 2017-10-27 Redhill Biopharma Ltd Formulations and methods of manufacturing formulations for use in colonic evacuation
US20150335672A1 (en) * 2014-05-22 2015-11-26 John Todd Kuenstner Treatment of Diseases Using Combination of Ultraviolet Blood Irradiation and Antibiotics
DK3419628T3 (da) 2016-02-26 2021-01-11 Debiopharm Int Sa Medikament til behandling af diabetiske fodinfektioner
ES2944535T3 (es) 2019-02-14 2023-06-22 Debiopharm Int Sa Formulación de afabicina, método para preparar la misma
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою
BR112022026615A2 (pt) 2020-06-30 2023-01-24 Redhill Biopharma Ltd Produtos combinados em dose tripla fixa de antibióticos, regime de dosagem, métodos e kits para tratamento de infecções por micobactérias pulmonares não tuberculosas
WO2025026423A1 (en) * 2023-08-02 2025-02-06 Shenzhen Pharmacin Co., Ltd. Compositions, their use and manufacture for treatment of gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440763A (en) * 1981-03-18 1984-04-03 Block Drug Company, Inc. Use of 4-aminosalicyclic acid as an anti-inflammatory agent
GB8919321D0 (en) * 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
JP2011511012A (ja) * 2008-02-08 2011-04-07 レッド ヒル バイオファーマ リミテッド 炎症性腸疾患を治療するための方法および組成物
JP2013508428A (ja) * 2009-10-26 2013-03-07 トーマス・ジュリアス・ボロディ 新規な腸の併用療法
US9468663B2 (en) 2009-10-26 2016-10-18 Thomas Julius Borody Enteric combination therapy
US10517922B2 (en) 2009-10-26 2019-12-31 Thomas Julius Borody Enteric combination therapy
US11344602B2 (en) 2009-10-26 2022-05-31 Thomas Julius Borody Enteric combination therapy
US11471505B2 (en) 2009-10-26 2022-10-18 Thomas Julius Borody Enteric combination therapy
US11612635B2 (en) 2009-10-26 2023-03-28 Thomas Julius Borody Enteric combination therapy
KR20140082982A (ko) 2011-09-20 2014-07-03 레드힐 바이오파마 엘티디 자기 면역 질환 치료용 조성물 및 방법
JP2014526548A (ja) * 2011-09-20 2014-10-06 レッド ヒル バイオファーマ リミテッド 自己免疫疾患を処置するための組成物および方法
US9901638B2 (en) 2011-09-20 2018-02-27 Redhill Biopharma Ltd. Composition and method for treating an autoimmune disease

Also Published As

Publication number Publication date
SI0971735T1 (sl) 2008-08-31
DK0971735T3 (da) 2008-07-07
JP2012126736A (ja) 2012-07-05
NO325947B1 (no) 2008-08-25
CY1109783T1 (el) 2013-09-04
DE69839261D1 (de) 2008-04-30
NO994778D0 (no) 1999-09-30
CA2285923A1 (en) 1998-10-08
US6277836B1 (en) 2001-08-21
JP2008024713A (ja) 2008-02-07
WO1998043667A1 (en) 1998-10-08
ATE389417T1 (de) 2008-04-15
EP0971735B1 (en) 2008-03-19
CA2285923C (en) 2013-03-12
ES2303351T3 (es) 2008-08-01
IL132145A (en) 2005-11-20
EP0971735A1 (en) 2000-01-19
NZ500696A (en) 2002-05-31
EP0971735A4 (en) 2004-02-25
DE69839261T2 (de) 2009-03-26
IL132145A0 (en) 2001-03-19
AR012304A1 (es) 2000-10-18
NO994778L (no) 1999-11-30
PT971735E (pt) 2008-06-02

Similar Documents

Publication Publication Date Title
US6277836B1 (en) Methods and compositions for treating inflammatory bowel disease
US6551632B2 (en) Methods and compositions for treating inflammatory bowel disease
JP4651816B2 (ja) クラミジアおよび類似細菌の感染と関連のある障害の治療のための方法および組成物
TWI573590B (zh) 治療自體免疫疾病之組成物及方法
EP4635573A2 (en) Delayed release deferiprone tablets and methods of using the same
KR20150118176A (ko) 헬리코박터 파일로리 치료용 약제학적 조성물
CN111870607A (zh) 盐酸米诺环素作为制备治疗自身免疫性葡萄膜炎药物的应用及其治疗方法
AU690661B2 (en) New use of quinoline-3-carboxamide compounds
JP2024523123A (ja) 去勢抵抗性前立腺がんの治療薬の調製におけるスタキオースの使用
JP2006502193A5 (enExample)
JP2006502193A (ja) 前立腺疾病を治療するためのヨクイニン油軟カプセル剤
AU750813B2 (en) Methods and compositions for treating inflammatory bowel disease
AU774329B2 (en) Methods and compositions for treating inflammatory bowel disease
WO2005074908A1 (en) Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome
JP2024516326A (ja) 去勢抵抗性前立腺がんの治療薬の調製におけるポラプレジンクの使用

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20060120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060414

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070813

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070921

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20071115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080214

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080925